Cardiovascular - Page 1
Stay up to date with the latest Cardiovascular updates from the global drugdevelopment industryLatest Cardiovascular Update
Actelion has reported that its macitentan drug, a dual endothelin receptor antagonist, met its primary endpoint in a study involving 742 patients suffering from pulmonary arterial hypertension...
> read more
QGC commences Phase I study of blood pressure monitoring drug
Quantum Genomics (QGC) has begun the Phase I clinical study of its drug candidate QGC001 in healthy volunteers following approval from the French Agency for Safety of Health Products...
Study says Vorapaxar drug with standard therapy reduces cardiovascular risk
Merck's investigational anti-thrombotic medicine Vorapaxar has demonstrated greater reduction in the risk of cardiovascular (CV) death, heart attack, stroke or urgent coronary...
AstraZeneca reports sub-analysis outcomes from PLATO study
AstraZeneca has reported the results from a sub-analysis of the PLATO genetic sub-study that evaluated the impact of poor metabolisers of clopidogrel in patients with acute coronary syndrome...
Pozen reports positive data from Phase 3 Studies of PA32540
Pozen has reported the positive top-line results from two pivotal Phase 3 clinical trials of PA32540, indicated for the secondary prevention of cardiovascular disease in patients at risk...
Cardium commences ASPIRE study of Generx drug
Cardium Therapeutics has begun the ASPIRE Phase 3 registration study to assess the therapeutic effects of Cardium's Generx (Ad5FGF-4) in patients with myocardial...
Celladon concludes financing to advance Mydicar drug
Celladon Corporation has secured a $43m equity financing to advance its lead investigational product candidate MYDICAR®, designed for the treatment of heart...
Hypercholesterolaemia drug Lomitapide shows efficacy in trial
Aegerion Pharmaceuticals drug candidate Lomitapide has demonstrated long-term safety and efficacy results in a 78-week Phase III clinical...
FDA clears Takeda Edarbyclor fixed-dose combination regimen
The US Food and Drug Administration (FDA) has approved Takeda Pharmaceutical's Edarbyclor as a treatment for hypertension in...
FDA grants Celladon's Mydicar drug fast-track status
The US Food and Drug Administration (FDA) has granted fast-track designation of Celladon's investigational product candidate Mydicar, which is designed to treat advanced heart...
European Commission clears Novartis Rasilez-based triple combination pill
The European Commission has approved Novartis Pharmaceuticals' Rasitrio, a Rasilez-based triple combination pill of aliskiren, amlodipine and hydrochlorothiazide that is used as a...
FDA accepts Amarin new drug application for AMR101
The US Food and Drug Administration (FDA) has accepted Amarin's new drug application for AMR101 (icosapent ethyl), a drug to treat patients with very high...
Bristol-Myers Squibb and Pfizer report apixaban trial results
Bristol-Myers Squibb and Pfizer have presented the results of the Phase III trial to compare apixaban (Eliquis) to enoxaparin in acutely ill medical...
Servier partners Miragen to develop microRNA-targeting drugs
European pharmaceutical company, Les Laboratoires Servier, has entered into a partnership agreement with Miragen Therapeutics, for advancing the research, development and commercialisation of...
